Daptomycin Hospira

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
06-04-2022
Tabia za bidhaa Tabia za bidhaa (SPC)
06-04-2022

Viambatanisho vya kazi:

daptomycin

Inapatikana kutoka:

Pfizer Europe MA EEIG

ATC kanuni:

J01XX09

INN (Jina la Kimataifa):

daptomycin

Kundi la matibabu:

Antibacterials for systemic use,

Eneo la matibabu:

Soft Tissue Infections; Skin Diseases, Bacterial

Matibabu dalili:

Daptomycin is indicated for the treatment of the following infections.Adult and paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections (cSSTI).Adult patients with right-sided infective endocarditis (RIE) due to Staphylococcus aureus. It isrecommended that the decision to use daptomycin should take into account the antibacterial susceptibility of the organism and should be based on expert advice.Adult and paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia (SAB).In adults, use in bacteraemia should be associated with RIE or with cSSTI, while in paediatric patients, use in bacteraemia should be associated with cSSTI.Daptomycin is active against Gram positive bacteria only. In mixed infections where Gram negative and/or certain types of anaerobic bacteria are suspected, daptomycin should be co-administered with appropriate antibacterial agent(s).Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Bidhaa muhtasari:

Revision: 13

Idhini hali ya:

Authorised

Idhini ya tarehe:

2017-03-22

Taarifa za kipeperushi

                                38
B. PACKAGE LEAFLET
39
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
DAPTOMYCIN HOSPIRA 350 MG POWDER FOR SOLUTION FOR INJECTION/INFUSION
daptomycin
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even
if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or nurse. This
includes any possible side effects not
listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Daptomycin Hospira is and what it is used for
2.
What you need to know before you are given Daptomycin Hospira
3.
How Daptomycin Hospira is given
4.
Possible side effects
5.
How to store Daptomycin Hospira
6.
Contents of the pack and other information
1.
WHAT DAPTOMYCIN HOSPIRA IS AND WHAT IT IS USED FOR
The active substance in Daptomycin Hospira powder for solution for
injection/infusion is daptomycin.
Daptomycin is an antibacterial that can stop the growth of certain
bacteria. Daptomycin Hospira is used in
adults and in children and adolescents (age from 1 to 17 years) to
treat infections of the skin and the
tissues below the skin. It is also used to treat infections in the
blood when associated with skin infection.
Daptomycin Hospira is also used in adults to treat infections in the
tissues that line the inside of the heart
(including heart valves) which are caused by a type of bacteria called
_Staphylococcus aureus._
It is also
used to treat infections in the blood caused by the same type of
bacteria when associated with heart
infection.
Depending on the type of infection(s) that you have, your doctor may
also prescribe other antibacterials
while you are receiving treatment with Daptomycin Hospira.
2.
WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN DAPTOMYCIN HOSPIRA
YOU SHOULD NOT BE GIVEN DAPTOMYCIN HOSPIRA
If 
                                
                                Soma hati kamili
                                
                            

Tabia za bidhaa

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Daptomycin Hospira 350 mg powder for solution for injection/infusion
Daptomycin Hospira 500 mg powder for solution for injection/infusion
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Daptomycin Hospira 350 mg powder for solution for injection/infusion
Each vial contains 350 mg daptomycin.
One mL provides 50 mg of daptomycin after reconstitution with 7 mL of
sodium chloride 9 mg/mL
(0.9%) solution for injection.
Daptomycin Hospira 500 mg powder for solution for injection/infusion
Each vial contains 500 mg daptomycin.
One mL provides 50 mg of daptomycin after reconstitution with 10 mL of
sodium chloride 9 mg/mL
(0.9%) solution for injection.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Daptomycin Hospira 350 mg powder for solution for injection/infusion
Powder for solution for injection/infusion.
A light yellow to light brown lyophilised cake or powder.
Daptomycin Hospira 500 mg powder for solution for injection/infusion
Powder for solution for injection/infusion.
A light yellow to light brown lyophilised cake or powder.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Daptomycin is indicated for the treatment of the following infections
(see sections 4.4 and 5.1).
-
Adult and paediatric (1 to 17 years of age) patients with complicated
skin and soft-tissue infections
(cSSTI).
-
Adult patients with right-sided infective endocarditis (RIE) due to
_Staphylococcus aureus. _
It is
recommended that the decision to use daptomycin should take into
account the antibacterial
susceptibility of the organism and should be based on expert advice
(see sections 4.4 and 5.1).
-
Adult and paediatric (1 to 17 years of age) patients with
_ Staphylococcus aureus _
bacteraemia (SAB).
In adults, use in bacteraemia should be associated with RIE or with
cSSTI, while in paediatric
patients, use in bacteraemia should be associated with cSSTI.
3
Daptomycin is active against Gram positive bacteria only (see section
5.1). In mixed infec
                                
                                Soma hati kamili
                                
                            

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 06-04-2022
Tabia za bidhaa Tabia za bidhaa Kibulgaria 06-04-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 18-04-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 06-04-2022
Tabia za bidhaa Tabia za bidhaa Kihispania 06-04-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 18-04-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 06-04-2022
Tabia za bidhaa Tabia za bidhaa Kicheki 06-04-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 18-04-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 06-04-2022
Tabia za bidhaa Tabia za bidhaa Kidenmaki 06-04-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 18-04-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 06-04-2022
Tabia za bidhaa Tabia za bidhaa Kijerumani 06-04-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 18-04-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 06-04-2022
Tabia za bidhaa Tabia za bidhaa Kiestonia 06-04-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 18-04-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 06-04-2022
Tabia za bidhaa Tabia za bidhaa Kigiriki 06-04-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 18-04-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 06-04-2022
Tabia za bidhaa Tabia za bidhaa Kifaransa 06-04-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 18-04-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 06-04-2022
Tabia za bidhaa Tabia za bidhaa Kiitaliano 06-04-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 18-04-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 06-04-2022
Tabia za bidhaa Tabia za bidhaa Kilatvia 06-04-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 18-04-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 06-04-2022
Tabia za bidhaa Tabia za bidhaa Kilithuania 06-04-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 18-04-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 06-04-2022
Tabia za bidhaa Tabia za bidhaa Kihungari 06-04-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 18-04-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 06-04-2022
Tabia za bidhaa Tabia za bidhaa Kimalta 06-04-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 18-04-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 06-04-2022
Tabia za bidhaa Tabia za bidhaa Kiholanzi 06-04-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 18-04-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 06-04-2022
Tabia za bidhaa Tabia za bidhaa Kipolandi 06-04-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 18-04-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 06-04-2022
Tabia za bidhaa Tabia za bidhaa Kireno 06-04-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 18-04-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 06-04-2022
Tabia za bidhaa Tabia za bidhaa Kiromania 06-04-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 18-04-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 06-04-2022
Tabia za bidhaa Tabia za bidhaa Kislovakia 06-04-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 18-04-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 06-04-2022
Tabia za bidhaa Tabia za bidhaa Kislovenia 06-04-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 18-04-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 06-04-2022
Tabia za bidhaa Tabia za bidhaa Kifinlandi 06-04-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 18-04-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 06-04-2022
Tabia za bidhaa Tabia za bidhaa Kiswidi 06-04-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 18-04-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kinorwe 06-04-2022
Tabia za bidhaa Tabia za bidhaa Kinorwe 06-04-2022
Taarifa za kipeperushi Taarifa za kipeperushi Kiaisilandi 06-04-2022
Tabia za bidhaa Tabia za bidhaa Kiaisilandi 06-04-2022
Taarifa za kipeperushi Taarifa za kipeperushi Kroeshia 06-04-2022
Tabia za bidhaa Tabia za bidhaa Kroeshia 06-04-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kroeshia 18-04-2018

Tafuta arifu zinazohusiana na bidhaa hii